Correspondence 0001827506-24-000103 from Tourmaline Bio, Inc. (TRML) (CIK 0001827506)
Tourmaline Bio, Inc. (TRML) (CIK 0001827506)
Date: Nov. 12, 2024 · CIK: 0001827506 · Accession: 0001827506-24-000103
AI Filing Summary & Sentiment
File numbers found in text: 333-283078
Letter
Document
November 12, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
RE: Tourmaline Bio, Inc.
Registration Statement on Form S-3
Filed November 7, 2024
File No. 333-283078
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tourmaline Bio, Inc.(the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 14, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Katherine Denby of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Katherine Denby of Cooley LLP, counsel to the Registrant at (202) 776-2070, or in her absence, Ryan Robinson, Chief Financial Officer of the Registrant.
Very truly yours,
TOURMALINE BIO, INC.
Show Raw Text
CORRESP 1 filename1.htm Document November 12, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards RE: Tourmaline Bio, Inc. Registration Statement on Form S-3 Filed November 7, 2024 File No. 333-283078 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Tourmaline Bio, Inc.(the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 14, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Katherine Denby of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Katherine Denby of Cooley LLP, counsel to the Registrant at (202) 776-2070, or in her absence, Ryan Robinson, Chief Financial Officer of the Registrant. Very truly yours, TOURMALINE BIO, INC. By: /s/ Brad Middlekauff Name: Brad Middlekauff Title: Corporate Secretary cc: Sandeep Kulkarni, Chief Executive Officer, Tourmaline Bio, Inc. Ryan Robinson, Chief Financial Officer, Tourmaline Bio, Inc. Divakar Gupta, Cooley LLP Brandon Fenn, Cooley LLP